Atlas Venture
Atlas Venture is a leading early-stage venture capital firm focused on investing in groundbreaking biotech innovation. With over 30 years of experience, Atlas Venture partners with top life science entrepreneurs to create and build breakthrough biotechnology companies. The firm is dedicated to translating groundbreaking science into life-changing medicines, having launched 70 startups from its incubator, with 25 medicines developed by its portfolio companies, 40 IPOs, and 34 M&A exits.
Atlas Venture
Portfolio
Nimbus Therapeutics received $4 billion upfront from Takeda for its TYK2 drug, marking one of the largest biotech licensing deals in recent years.
#Biotechnology
Korro Bio, an RNA editing startup, is expected to take its spot on the Nasdaq in the fourth quarter, having raised $117 million.
#Biotechnology
Eli Lilly will pay up to $1.925 billion for Versanis' weight loss drug, marking a significant acquisition in the biotech sector.
#Biotechnology
Mariana Oncology raised $175 million in a Series B round, focusing on developing radiopharmaceuticals.
#Radiopharmaceuticals
Intellia received FDA approval to start a phase 3 trial of its in vivo CRISPR-based gene editing therapy.
#Gene Editing
Q32 Bio will take Homology Medicines’ place on the Nasdaq to fund Phase II trials in autoimmune and inflammatory conditions.
#Biotechnology
Diagonal Therapeutics raised $128 million to discover agonist antibodies.
#Biotechnology
Obsidian Therapeutics raised $160 million for its solid tumor cell therapy program.
#Biotechnology
Day One’s Ojemda received FDA accelerated approval for treating pediatric brain tumors.
#Biotechnology
Novartis acquired Mariana Oncology for $1 billion to bolster its radiopharma assets.
#Radiopharmaceuticals
Pheon Therapeutics raised $120 million to test three assets in the clinic.
#Biotechnology
Sionna Therapeutics is reviving AbbVie’s cystic fibrosis drugs, aiming to compete with Vertex.
#Biotechnology
Intellia’s gene editing therapy succeeded in a Phase 2 study for a genetic swelling condition.
#Gene Editing
Scorpion’s STX-478 showed promising efficacy and tolerability in an early cancer trial.
#Biotechnology